Gilead Sciences has found a shiny new package for one of its cancer assets, inking a research pact worth up to $300 million ...

Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.

Gilead Sciences trades at $117.95 and has moved in lockstep with the market. Its shares have returned 5.5% over the last six ...

Gilead Sciences Inc. (NASDAQ:GILD) is one of the best stocks for the next decade. On December 12, Morgan Stanley raised the ...

Gilead Sciences advances global biopharmaceutical research as companies within the nasdaq 100 index shape healthcare ...

AbbVie and Gilead Sciences each used the holiday season to reward their pipelines with a new clinical-stage cancer drug. | ...

Bay Area drugmaker Gilead Sciences has promoted longtime company attorney Keeley Wettan to executive vice president, general counsel, legal and compliance, effective immediately. Wettan, who joined ...

Gilead Sciences promoted Keeley Wettan to EVP, general counsel, legal and compliance. She will join the senior leadership ...

Gilead will pay Repare $25m upfront, and up to an additional $5m upon completion of certain technology transfer activities.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Much has changed since Daniel O’Day, chairman and CEO ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that Mark Genovese, MD, has been appointed Senior Vice President, Inflammation, with responsibility for ...

Daniel O’Day and a group of Gilead employees visited with San Francisco Community Health Center staff last fall. Image courtesy of San Francisco Business Times. Originally published by SAN FRANCISCO ...